Thought Leadership
'Intended Purpose' of a Flower: Gauging Patent Invalidity Based on the Public Use of Plants and Genetic Information
Ross E. Blau, Matthew S. Murphy
Reuters Westlaw Today
June 8, 2023
What’s Happening in Austria, Switzerland, and Lithuania? Conversations With Competition Law Enforcers at the 2023 Spring Meeting
Jeny M. Maier
Our Curious Amalgam
June 5, 2023
Supreme Court confirms full scope enablement standard in Amgen v. Sanofi
Patrick Doyle, Thomas K. Hedemann
Reuters
May 31, 2023
Would Congress' Proposed ITC Reforms Thwart NPEs?
Ramya Auroprem, Brian P. Johnson, Don Z. Wang 王哲楠
Law360
May 26, 2023
Effects of GSK v Teva Ripple after SCOTUS Denies Cert
Ross E. Blau, Chad A. Landmon
Life Sciences IP Review
May 23, 2023
FDA's Digital Health Technologies Framework Addresses Important Challenges
Chad A. Landmon, Gabriella M. McIntyre
Cell & Gene, Bioprocess Online, Clinical Leader, Med Device Online, Outsourced Pharma, and Pharmaceutical Online
May 16, 2023
Axinn IP Update: Supreme Court Denies Cert. in Skinny Label Case, but the Impacts from GSK v. Teva Continue
Ross E. Blau, Chad A. Landmon, Matthew S. Murphy
May 15, 2023
USPTO’s ANPRM Sets the Stage for Latest Revamp of the Discretionary Denial Process
Eric Krause, Jeannine Yoo Sano
IPWatchdog
May 7, 2023
LIV and Let Live? The Antitrust Fight Between the PGA and LIV Golf
Kail J. Jethmalani
Our Curious Amalgam
April 24, 2023
Has the Risk of Information Exchanges Shifted? DOJ’s Withdrawal of Healthcare Policy Statements
Leslie C. Overton
Our Curious Amalgam
April 10, 2023
The Not-So-Silk Road: The Proliferating Regulatory Obstacles to Chinese Investment in the U.S.
David R. Pearl, Isabella Solórzano
CPI Antitrust Chronicle
March 29, 2023
Axinn IP Update: The Supreme Court Hears Arguments About the Enablement Standard in Amgen v. Sanofi
Patrick Doyle, Thomas K. Hedemann, Ted Mathias
March 28, 2023
The FTC’s Proposed Rule on Non-Competes: What it Means for the Health Care Industry
Richard B. Dagen
AHLA Speaking of Health Law
March 17, 2023
Antitrust Cartel Leniency and Sentencing Handbook
James W. Attridge, Danielle D. Irvine, Daniel K. Oakes, Duncan Weals, Heather C. Zuckert
American Bar Association
March 15, 2023
A Sickness or a Cure for High Drug Prices? Why PBMs are Under the Antitrust Microscope
Jeny M. Maier
Our Curious Amalgam
March 13, 2023
Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity
Chad A. Landmon, Gabriella M. McIntyre
Clinical Leader
February 23, 2023
Antitrust Focus on PE Expands Beyond Just M&A
Jeny M. Maier
PE Hub
February 15, 2023
Cryptocurrency Companies Could Face Liability Under CUTPA
Nicholas Duffee
Connecticut Law Tribune
February 7, 2023
Shift in Health Care Antitrust Prosecutions is Likely
James W. Attridge, Tasneem U. Chowdhury**, Daniel K. Oakes
Law360
February 7, 2023
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2023
Axinn Update
January 26, 2023
Axinn Antitrust Insight: FTC Issues Proposed Rule Banning Employee Non-Compete Clauses
Axinn Update
January 9, 2023
Federal Circuit Reverses Course on ‘Appropriate Deference’ in Indefiniteness Determinations
Ramya Auroprem, Eric Krause, Don Z. Wang 王哲楠
Bloomberg Law
January 5, 2023
The Regulatory Labyrinth of Stem Cell Treatments
Chad A. Landmon
Cell & Gene
December 20, 2022
A Power Grab Too Far? (Part 2) The European Commission Investigation in Illumina/Grail
Jeny M. Maier
Our Curious Amalgam
December 19, 2022
The FTC’s New Unfair Methods of Competition Policy Statement: To What Extent Will The Approach Survive in Court?
Sam D. Sherman**, Koren W. Wong-Ervin
Competition Policy International
December 18, 2022
United States: E-Commerce and Big Data Merger Control
Daniel S. Bitton, Neelesh Moorthy, Leslie C. Overton
GCR: Digital Markets Guide – Second Edition
November 25, 2022
Axinn Antitrust Insight: FTC Policy Statement Re Section 5
Axinn Update
November 21, 2022
Axinn IP Update: Federal Circuit Confirms That Prosecution Disclaimer Is Not Binding on the Patent Office in an Ongoing PTAB Proceeding But Will Bind Future Proceedings
Patrick Doyle, Jeannine Yoo Sano, Don Z. Wang 王哲楠
November 18, 2022
The Department’s Corporate Criminal Enforcement Policy Changes: Implications for Antitrust Practice
James W. Attridge
Competition Policy International
November 14, 2022
Who is Rahul Rao? Meet the Newest Deputy Director of the FTC Bureau of Competition
Jeny M. Maier
Our Curious Amalgam
November 14, 2022
Criminal Monopolization Plea Fuels DOJ Antitrust Mandate
Daniel K. Oakes, Tiffany Rider
Law360
November 1, 2022
Axinn Antitrust Insight: Public and Regulatory Sentiment Point to Increased Healthcare Merger Enforcement
Axinn Update
October 31, 2022
3 Years In, Procurement Collusion Strike Force Hits Its Stride
James W. Attridge
October 27, 2022
Axinn Antitrust Insight: Antitrust Division Obtains First Conviction for Labor-Market Collusion
Axinn Update
October 27, 2022
Axinn Antitrust Insight: Judges Skeptical of Recent Biden Administration Merger Challenges
Axinn Update
October 26, 2022
Axinn Antitrust Insight: US Department of Justice Forces Interlocking Board Members to Resign
Axinn Update
October 21, 2022
United States: Antitrust in Organised Sports
Nicholas E.O. Gaglio, Zachary D. Stross
Global Competition Review – Americas Antitrust Review 2023
October 4, 2022
The Biden Administration’s Changing Approaches to Antitrust in Health Care
Leslie C. Overton
AHLA Speaking of Health Law
September 20, 2022
Biden’s Antitrust Crackdown: Five Things Dealmakers Should Know
Jeny M. Maier
PE Hub
September 12, 2022
USA: Law and Practice
Lisl J. Dunlop, Bradley Justus, Megan Walden
Chambers Global Practice Guides – Merger Control 2022
August 8, 2022
Pharmaceutical Supply Chain – Patent Considerations
Ross E. Blau, Aziz Burgy
American Bar Association
July 28, 2022
LEXIS-NEXIS Antitrust Report
James K. Hunsberger
LEXIS-NEXIS
June 29, 2022
Second Circuit: Southern District of New York - Edition 3
Lisl J. Dunlop
Global Competition Review
June 24, 2022
Axinn Litigation Insight: Supreme Court Limits Reach of Discovery for Foreign Arbitrations
Axinn Update
June 22, 2022
When a Claimed Trade Secret Isn't in Fact a Secret
Francis Henry Morrison
Law360
June 7, 2022
Labor Markets in Healthcare Transactions: A Work in Progress
Lisl J. Dunlop, Matthew K. Hayden
CPI Antitrust Chronicle
June 1, 2022
US Competition Law Issues for FinTechs
Nicholas E.O. Gaglio, Denise L. Plunkett
Financier Worldwide
June 2022
True Crime? An Investigation Into DOJ’s Recent Policy Change on Criminal Monopolization Prosecutions
James K. Hunsberger, Tiffany Rider
Our Curious Amalgam
May 30, 2022
Antitrust Litigation is Coming to Cannabis
Lisl J. Dunlop, Sam D. Sherman**
Cannabis Business Executive
May 25, 2022
Criminal Monopolization Prosecutions: DOJ's Recent Policy Change, Past Cases, and Potential Obstacles
James K. Hunsberger, Tiffany Rider
ABA The Antitrust Counselor
May 23, 2022
Axinn Antitrust Insight: Confirmation of Third Democratic FTC Commissioner Secures Majority, Setting Stage for Aggressive and Unconventional Agenda
Axinn Update
May 13, 2022
The Uncertain Future of Patent Indefiniteness Under Federal Circuit's Deference Standard
Ramya Auroprem, Eric Krause, Don Z. Wang 王哲楠
Bloomberg Law
May 6, 2022
Will DOJ Really Bring Criminal Monopolization Charges?
Tiffany Rider
Legal Speak
April 30, 2022
Axinn Antitrust Insight: DOJ Updates Antitrust Leniency Program and Agencies Continue Shift to Increase Merger Enforcement
Axinn Update
April 19, 2022
Axinn Antitrust Insight: DOJ Officials Raise Specter of Criminal Monopolization Prosecutions
Axinn Update
March 15, 2022
Big Trouble for Biglari Under the HSR Act – and Why Cannabis Operators Should Take Note
Lisl J. Dunlop, Sam D. Sherman**
Cannabis Business Executive
March 2, 2022
Teaching a Judge or Jury Enough About Regression to Trust (or Mistrust It)
Andrea N. Rivers
ABA Antitrust Law Section’s Trust and Trade Podcast
March 1, 2022
China’s New Privacy and Data Security Statutes Further Complicate U.S. Litigations
Brooke J. Oppenheimer, Don Z. Wang 王哲楠
Mealey's Data Privacy Law Report and Mealey’s Litigation Report Discovery
February 2022
Axinn IP Update: Federal Circuit Denies Petition for Rehearing En Banc in GSK v. Teva
Ross E. Blau, Aaron Z. Savit, PhD
February 17, 2022
Axinn IP Update: Federal Circuit Confirms That AAPA Cannot Be the Basis for IPRs, But Leaves the “Basis” Determination Question Open
Ramya Auroprem, Eric Krause, Don Z. Wang 王哲楠
Axinn Update
February 3, 2022
Axinn Antitrust Insight: FTC Announces New HSR Thresholds for 2022
Axinn Update
January 26, 2022
Axinn Antitrust Insight: U.S. Antitrust Agencies to Significantly Revise and Broaden Merger Guidelines
Axinn Update
January 24, 2022
2021's Biggest Antitrust Developments and What to Expect in 2022
Jeny M. Maier
AHLA Speaking of Health Law
January 18, 2022
Who’s Who Legal – Thought Leaders Competition 2022
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider, Michael L. Keeley
January 18, 2022
Top Ten 2022: Provider M&A Faces New Antitrust Headwinds
Lisl J. Dunlop
AHLA Speaking of Health Law
January 14, 2022
Top Ten Issues in Health Law 2022
Lisl J. Dunlop
AHLA Health Law Connections
January 1, 2022
The Center for Biosimilars Interview Series: Legal Perspectives in Biosimilars
Chad A. Landmon
The Center for Biosimilars
December 27, 2021
Environment Has Become a Global Merger Control Issue
Caroline Boisvert
Law360
December 17, 2021
Federal Government Enhances Focus on Labor in Antitrust Reform
Neelesh Moorthy, David R. Pearl
Daily Journal
November 17, 2021
Achieving Cross-Matter Review Discipline, Cost Control, and Efficiency
Jason Rylander
Law & Candor
November 16, 2021
United States: E-Commerce and Big Data Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR: Digital Markets Guide
November 2021
Axinn Antitrust Insight: FTC Increasing Remedy Burdens
Axinn Update
October 28, 2021
Antitrust and Healthcare Inequity
Lisl J. Dunlop
Eleanor M. Fox Liber Amicorum - Antitrust Ambassador to the World
October 27, 2021
Extraterritoriality: Approaches Around the World and Model Analysis
Koren W. Wong-Ervin
Eleanor M. Fox Liber Amicorum - Antitrust Ambassador to the World
October 27, 2021
Remedies in the Context of Multi-Jurisdictional Mergers
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2021
Best Practices in the Acquisition of a Government Contractor
Rachel J. Adcox
Best Practices in the Acquisition of a Government Contractor
October 7, 2021
Axinn IP Update: Proposed Legislation Aims at "Restoring the America Invents Act"
Rebecca L. Clegg
Axinn Update
October 5, 2021
The Other Side of the Coin: Complementarity in Mergers of Multiproduct Firms
Craig D. Minerva
Antitrust Magazine Online
October 2021
Axinn Antitrust Insight: Changes Afoot at the FTC
Axinn Update
September 27, 2021
Happy 10th Birthday
Aziz Burgy, Aaron Z. Savit, PhD
Intellectual Property Magazine
September 27, 2021
Rethinking the Partnership Model to Foster Inclusion
Rachel J. Adcox
ABA Law Practice Today
September 15, 2021
U.S. Antitrust Enforcement in the Trump Administration
Daniel S. Bitton
Tijdschrift Mededingingsrecht in de Praktijk
August 2021
How I Made Partner: Craig Reiser
Craig M. Reiser
Law.com
August 9, 2021
Second Circuit: Southern District of New York – Edition 2
Lisl J. Dunlop
Global Competition Review
July 2021
SCOTUS Decides Arthrex: Much Ado About Inter Partes Reviews
Aziz Burgy
Bloomberg Law
July 15, 2021
The Center for Biosimilars Interview: Axinn IP Chair Provides Analysis of Biden Biosimilars Initiative
Chad A. Landmon
The Center for Biosimilars
July 14, 2021
Axinn Antitrust Insight: White House Issues Executive Order Aimed at Increasing Antitrust Enforcement and Promoting Competition
Axinn Update
July 12, 2021
A Tougher M&A Regulatory Environment
Lisl J. Dunlop, Jeny M. Maier
Pharma Manufacturing
June 25, 2021
Health Care Antitrust Enforcement Homes in on Non-Hospital Transactions
Lisl J. Dunlop, Angela M. Farren, Jeny M. Maier
AHLA PG Briefing
June 25, 2021
New U.S. Legislation Creates Momentum for Biosimilars
Ramya Auroprem, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online
June 25, 2021
Axinn Antitrust Insight: Lina Khan Sworn in as New FTC Chair
Axinn Update
June 17, 2021
FDA's Longtime Approach to New Chemical Entity Designations Now Codified
Ramya Auroprem, Stacie L. Ropka, PhD
Outsourced Pharma and Pharmaceutical Online
June 14, 2021
Labor Markets and the Rise of No-Poach Litigation
Carol Xianxiao Liu
American Bar Association
June 4, 2021
Klobuchar Proposes Bill That Would Overhaul U.S. Antitrust Law
David R. Pearl
Daily Journal
June 1, 2021
Extra-Territoriality: Global Dictionary of Competition Law
Koren W. Wong-Ervin
Global Dictionary of Competition Law, Concurrences
May 21, 2021
Opinion: Purple Book Patent Listings Are Only a First Step
Ted Mathias, Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
The Center for Biosimilars
May 8, 2021
Axinn Antitrust Insight: Supreme Court Limits FTC's Ability to Seek Equitable Monetary Relief
Axinn Update
April 30, 2021
Jota “Digital Competition” Series Article
Koren W. Wong-Ervin
Jota
April 16, 2021
Health Insurance Compliance Steps After Antitrust Reform
Lisl J. Dunlop, Thomas G. Rohback
Law360
April 7, 2021
Axinn Antitrust Insight: DOJ Continues Criminal Enforcement in Labor Markets
Axinn Update
April 6, 2021
Axinn Antitrust Insight: FTC Challenges Illumina’s Acquisition of Grail
Axinn Update
April 6, 2021
Axinn Antitrust Insight: FTC Launches Multinational Group to Tackle Pharmaceutical Deals
Axinn Update
April 6, 2021
Will Skinny Labelling Survive?
Aziz Burgy
Intellectual Property Magazine
March 25, 2021
How Far Can You Go? U.S. Merger Enforcement Under Section 2 of the Sherman Act
Koren W. Wong-Ervin
Our Curious Amalgam
March 22, 2021
International Developments in Healthcare Antitrust Litigation
Angela M. Farren
ABA Antitrust Law Section International Committee
March 2021
If You Can’t Beat Them and You Can’t Join Them: Geisinger and Evangelical’s Settlement with DOJ Limits the Scope of Their Partial Acquisition and Collaboration
Jeny M. Maier
AHLA Health Law Weekly
March 12, 2021
IP and Collaboration
Chad A. Landmon
Pharmaceutical Executive
March 11, 2021
Interview on the FDA’s Emergency Use Authorization Process for COVID-19 Vaccines
Chad A. Landmon
Pharmacy Times
March 2021
Axinn IP Update: Where is the Federal Circuit Heading in the Skinny Labeling Case?
Chad A. Landmon
Axinn Update
March 4, 2021
Axinn IP Update: Federal Circuit Says Functional Patent Claims Must Clear "High Hurdles"
Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
Axinn Update
February 12, 2021
Axinn IP Update: Federal Circuit Agrees to Reconsider Controversial “Skinny Label” Decision
Chad A. Landmon
Axinn Update
February 10, 2021
Cost and Opportunity in Suspending Early Merger Clearances
Leslie C. Overton, Sam D. Sherman**
Law360
February 8, 2021
Member Spotlight: Francis H. Morrison
Francis Henry Morrison
Voice of Experience
January 27, 2021
The Next Four Years: Antitrust Enforcement on an Upward Trajectory
Lisl J. Dunlop
Concurrences Competition Law Review
January 19, 2021
How President-Elect Biden’s Cabinet Nominations May Impact Pharmacy This Year
Chad A. Landmon
Pharmacy Times
January 15, 2021
Highlights From the OECD Roundtable on the Role of Competition Policy in Promoting Economic Recovery
Caroline Boisvert
Competition Policy International
January 11, 2021
The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
Chad A. Landmon
Contract Pharma
January 5, 2021
If You Can’t Beat Them and You Can’t Join Them: Geisinger-Evangelical’s Warning for Partial Acquisitions
Jeny M. Maier
AHLA PG Briefing
January 4, 2021
Frandly Fire
Thomas K. Hedemann, Ted Mathias, Gabriella M. McIntyre
Intellectual Property Magazine, December 2020 / January 2021 Issue
When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns
Francis Henry Morrison, Jason Murata
January 2021
Opinion: The Legal and Regulatory Year in Review
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
December 24, 2020
Our Journey to Voting by Mail-In Ballot in North Carolina in 2020
Francis Henry Morrison
Voice of Experience
December 16, 2020
DOJ's 1st Wage-Fixing Indictment is a Warning to Cos.
Tiffany Rider
Law360
December 14, 2020
Balancing Incentives to Innovate in Upstream Wireless Technology Markets with Exit Concerns in Midstream Component Product Markets
Koren W. Wong-Ervin
Douglas H. Ginsburg – An Antitrust Professor on the Bench Liber Amicorum Volume II
December 9, 2020
The US DOJ Indicts a Former Owner of a North Texas Physical Therapist Staffing Company for Conspiring With Competitors to Suppress Wages (Neeraj Jindal)
Tiffany Rider
Concurrences e-Competitions Bulletin
December 9, 2020
Antitrust Treatment of Acceleration Provisions in Hatch-Waxman Settlements
Michael L. Keeley
FDLI’s Update Magazine, Winter 2020 Issue
December 7, 2020
How Justice Barrett’s Confirmation Might Impact Patent Eligibility
Aaron Z. Savit, PhD
World IP Review
December 1, 2020
Top 10 IPR Pitfalls at the Institution Stage
Aziz Burgy
ABA Landslide magazine, Vol. 13, No. 2, November / December 2020 Issue
What the Potential Elimination of the Biologics Price Competition and Innovation Act Means for Pharmacy
Chad A. Landmon
Pharmacy Times
December 1, 2020
Axinn FDA Update: Insights on the MODERN Labeling Act
Chad A. Landmon
Axinn Update
November 20, 2020
Seeking "Mens Sana in Corpore Sano" in a Pandemic
Francis Henry Morrison
Voice of Experience
November 17, 2020
Buyer Beware: Considerations for a Divestiture Buyer in “Litigating the Fix”
Jeny M. Maier
3 Antitrust Report 22, LexisNexis
November 2020
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
Chad A. Landmon
The Center for Biosimilars
November 11, 2020
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 2020
The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Jason Murata
November 2020
A Look at the Recent DOJ Complaint in U.S. v. Geisinger
Lisl J. Dunlop
AHLA Speaking of Health Law
October 12, 2020
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2020
What Lemons Teach Us About Privacy and Competition
John D. Harkrider
ABA Antitrust Magazine
Fall 2020
Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
Chad A. Landmon
Axinn Update
September 21, 2020
Tuning in to Covered Business Method Review's Series Finale
Eric Krause, Pan Lee
Law360
September 15, 2020

View Archived Thought Leadership ›

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.